Biodel (BIOD) Plans to Submit NDA for VIAject(R) to FDA
Up)
Biodel Inc. (Nasdaq: BIOD) announced today its plan to submit a new drug application to the U.S. FDA in the second half of this year for approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel's investigational ultra-rapid-acting injectable human insulin intended for meal-time use by people with Type 1 and Type 2 diabetes. The NDA will be based upon results from multiple pharmacokinetic and pharmacodynamic studies as well as two completed Phase 3 studies of VIAject(R) in patients with Type 1 and Type 2 diabetes.
You May Also Be Interested In
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- Chelsea Therapeutics (CHTP) Completes End-of-Review Meeting with FDA Over Northera NDA
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
